Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome. - Wikidata - wikimedia - TriplyDB

Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome.

Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome.

http://www.wikidata.org/entity/Q35536279

about

Community acquired bacterial pneumonia Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials Systematic review regarding metabolic profiling for improved pathophysiological understanding of disease and outcome prediction in respiratory infections Community-acquired pneumonia: identification and evaluation of nonresponders New aspects in the management of pneumonia Cardiac complications in patients with community-acquired pneumonia: a systematic review and meta-analysis of observational studies Tools for outcome prediction in patients with community acquired pneumonia.Risk of heart failure after community acquired pneumonia: prospective controlled study with 10 years of follow-up Prior cardiovascular disease increases long-term mortality in COPD patients with pneumonia.Moxifloxacin monotherapy versus combination therapy in patients with severe community-acquired pneumonia evoked ARDS.Age-related differences in management and outcomes in hospitalized healthy and well-functioning bacteremic pneumococcal pneumonia patients: a cohort study.Predicting treatment failure in patients with community acquired pneumonia: a case-control study.Pneumococcal pneumonia: differences according to blood culture results.A leukocyte score to improve clinical outcome predictions in bacteremic pneumococcal pneumonia in adults.Causes of non-adherence to therapeutic guidelines in severe community-acquired pneumonia Managing the safety of inhaled corticosteroids in COPD and the risk of pneumonia.Can We Predict Oral Antibiotic Treatment Failure in Children with Fast-Breathing Pneumonia Managed at the Community Level? A Prospective Cohort Study in Malawi.In vivo efficacy and molecular docking of designed peptide that exhibits potent antipneumococcal activity and synergises in combination with penicillin.Early cardiac arrest in patients hospitalized with pneumonia: a report from the American Heart Association's Get With The Guidelines-Resuscitation Program.Minor criteria of Infectious Disease Society Of America/American Thoracic Society for severe community-acquired pneumonia can predict delayed treatment response Risk of pneumonia among patients with chronic kidney disease in outpatient and inpatient settings: a nationwide population-based study.Etiology of community-acquired pneumonia in a population-based study: link between etiology and patients characteristics, process-of-care, clinical evolution and outcomes Treatment with macrolides and glucocorticosteroids in severe community-acquired pneumonia: A post-hoc exploratory analysis of a randomized controlled trial.Inpatient treatment of community-acquired pneumonias with integrative medicine.A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (tifacogin) in patients with severe community-acquired pneumonia The National Early Warning Score (NEWS) for outcome prediction in emergency department patients with community-acquired pneumonia: results from a 6-year prospective cohort study.Antibiotic expected effectiveness and cost under real life microbiology: evaluation of ertapenem and ceftriaxone in the treatment of community-acquired pneumonia for elderly patients in Spain Pneumonia, Acute Respiratory Distress Syndrome, and Early Immune-Modulator Therapy.Risk factors and severity scores in hospitalized patients with community-acquired pneumonia: prediction of severity and mortality.The hospitalist perspective on treatment of community-acquired bacterial pneumonia.White Blood Cell Counts, Alcoholism, and Cirrhosis in Pneumococcal Pneumonia Clinical Management of Community Acquired Pneumonia in the Elderly Patient.The Clinical Management Of Lower Respiratory Tract Infections.In-hospital mortality risk factors in community acquired pneumonia: evaluation of immunocompetent adult patients without comorbidities.A 44-year-old man with a parapneumonic effusion.Outcomes of early, late, and no admission to the intensive care unit for patients hospitalized with community-acquired pneumonia.Inhaled corticosteroids and systemic inflammatory response in community-acquired pneumonia: a prospective clinical study.Development and validation of a clinical prediction rule for severe community-acquired pneumonia.Pneumococcal serotypes in adult non-invasive and invasive pneumonia in relation to child contact and child vaccination status.Health care-associated pneumonia (HCAP): a critical appraisal to improve identification, management, and outcomes--proceedings of the HCAP Summit.

P2860

Q22241379-C48874A4-A5DC-4A89-9EB9-A4D93E3DA73D Q24655866-11A91BD8-2DD9-4B1C-B50F-50D1A0C26222 Q26782662-65F966A0-4EFB-4B95-826C-8C791ED58C87 Q27002420-53E9599B-BD6C-4F41-9149-D3705D1B7CDA Q28080025-961FED43-5211-46AE-B08F-86EAEA59415D Q28743162-1C9A47A5-63DF-4E30-B71A-905B4A28032D Q30240254-CD4CF3EB-2D0A-46FF-9290-CCB26CCB44DF Q33647377-0B360FBA-D59F-4752-9579-F455A0C0AD78 Q33790733-41621016-4CCF-4089-A56B-C831E37D64E8 Q33801234-0BEDC60B-D8F3-4C53-B7D7-78D71982B612 Q33816163-783BB0EB-67DF-4DB6-BB62-9D7232520F58 Q33906338-FE386FE2-29AD-40DE-B97F-95C8A44AB762 Q34021594-9EC24F4E-A8B6-4E1D-8134-6BCBBE8C9F97 Q34801968-A1F5892A-0033-4D0A-9714-CF4B1A7ED1DD Q35414598-636F99CD-F0C4-465E-A212-B6FD2194CA80 Q35675040-9D05C6FB-59FB-4A98-B289-FD5420E57081 Q35757515-51F40B50-553A-42E0-B536-8203FC36A22F Q35833971-A1C0D56F-A736-4E9F-B4F4-393BC094316D Q36009084-277BE616-4B30-4248-B768-3C9CE2FFC4D7 Q36134607-4ABFBE96-C4FA-4B8E-A051-3AB5C43D0B01 Q36152618-AA133AF1-729D-4260-A832-2BAD7CA7D264 Q36291044-14299865-2860-4E56-B32D-5C9A214FC28D Q36406243-249BF29F-A3BB-41ED-A2A4-3FBB8C138F93 Q36907878-4BFF5043-0838-4C00-AB5C-C6BBED05E116 Q37210059-7BA802B2-5F00-4994-964F-91D656E76C6A Q37312188-92EC5C89-0433-4E86-A9CF-959BCB5167E2 Q37591904-EE68B2BC-044A-4D8B-9E3C-7B85F07B5129 Q37690927-47F8BDFA-AF82-4D66-BE22-76C5D4920EEA Q37870823-B97A0F61-38E6-4D9A-99B6-1A19DB8DE8D7 Q38200827-3FEB78B4-9911-42BC-9C76-9279E166B36B Q38668858-BA8513CC-B8F6-4A07-9DB4-3C7EC1D422A2 Q38969066-62272F43-C4A1-4E54-80DE-6C4AB9FB82C5 Q40785029-05E25F29-050E-4C6E-9747-C31B36499998 Q41142310-4906786A-A3A7-4198-B5FA-0CC63B7A6A9C Q42099942-A964C755-D996-477D-B903-F8D5722781F9 Q43801396-12883DCB-9F7C-490F-9DDB-2F59AE7DB0CF Q44211958-FB0EEB48-92AA-4708-AF9D-26E3DF216C49 Q44818174-EE302A0E-D462-4B69-B118-8AD466856328 Q45836463-9B912004-AC7F-4727-9FF1-B83B93F3C01B Q46076297-9B22A49E-C649-4E61-883B-9D61E8A444DE

P2860

Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome.

http://www.wikidata.org/entity/Q35536279

description

2004 nî lūn-bûn

@nan

2004 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Risk factors of treatment fail ...... lications for disease outcome.

@ast

Risk factors of treatment fail ...... lications for disease outcome.

@en

type

label

Risk factors of treatment fail ...... lications for disease outcome.

@ast

Risk factors of treatment fail ...... lications for disease outcome.

@en

prefLabel

Risk factors of treatment fail ...... lications for disease outcome.

@ast

Risk factors of treatment fail ...... lications for disease outcome.

@en

P1433

Q35536279-6975D621-43C0-4B22-B43E-43A0B0364D46

P1476

Q35536279-3009209E-BA23-40DC-B7ED-B9E17C587B25

P2093

Q35536279-01A86FFF-DFBD-4AF5-B309-B381FDB6ED24

Q35536279-136F0B79-20FA-4EEB-AD59-84589001AC3C

Q35536279-1BF4CB88-D67A-4331-BFA1-BBE166A8AB14

Q35536279-42492B93-DA5A-4348-B2B7-6B63BF8F2595

Q35536279-553F2D15-BCFE-4534-B19B-18F671C42363

Q35536279-5D6D0C8D-4A19-46C7-ADB1-1366C414BC11

Q35536279-6669524E-BAD2-4807-825F-B17604336054

Q35536279-66C9FA6A-E7DE-43A0-94F4-1669080885D8

Q35536279-6AE1AB40-B207-4D24-A04C-B668A2C1D590

Q35536279-9227FAD7-30F0-4FF2-8504-EE3FE19BAABC

P2860

Q35536279-0ADE9E17-8A7E-439B-9602-928AC9E54F8E

Q35536279-0C349ADB-14CD-489E-899A-85A481B1B9BA

Q35536279-1BB2A659-19A6-4EFE-B307-A691ED493700

Q35536279-1E4F2C6F-BD66-4728-9E05-FEC97FC2B036

Q35536279-25D3204A-1A40-4B01-A03F-201AE6DF712F

Q35536279-34D30130-5077-4673-9C55-57924A3FF964

Q35536279-3692105F-65AF-4FAA-B373-471409392F5C

Q35536279-394DEFFA-EEFA-4B27-BEA9-45F0D475B50C

Q35536279-4E542964-24E0-4996-BA50-A32B1AA40B1C

Q35536279-4F6EAC8D-C7D9-41DA-BD98-22489FA36575

P304

Q35536279-5F583606-43E9-48B0-966C-A93F4C7311E7

P31

Q35536279-2E6D7EDA-CCE2-47B9-850C-FF8CA4C7E472

P356

Q35536279-15CF5034-2E2D-4A7C-9F67-8132E4431A23

P407

Q35536279-08C5190B-FA28-4FBF-9091-C2F3AEF7578B

P433

Q35536279-924B9E6A-B674-4604-931C-E26DAFBEDFBC

P478

Q35536279-91B0AC2B-8CD1-4408-B50C-BE69A8345AE7

P50

Q35536279-70C21FA0-974F-4DCC-8FC1-5C0CC0BBB16A

Q35536279-BDA53507-BB63-41AD-854F-BA70612A9B5C

P577

Q35536279-01CB1ABA-88F5-414D-AF6D-DAA93474B1AD

P5875

Q35536279-84126F49-40CD-45A7-884F-BEF0116F43A5

P698

Q35536279-C4097721-6DA6-44FD-A856-259A47CFA464

P921

Q35536279-214492D6-0E12-4794-B8E8-D10520F7908D

P932

Q35536279-2E62BA02-C0ED-44DB-8697-0D796F262135

P356

THX.2003.017756

P1433

P1476

Risk factors of treatment fail ...... plications for disease outcome

@en

P2093

A Torres

http://www.w3.org/2001/XMLSchema#string

C Alvarez

http://www.w3.org/2001/XMLSchema#string

C Puzo

http://www.w3.org/2001/XMLSchema#string

D Pérez

http://www.w3.org/2001/XMLSchema#string

F Rodríguez de Castro

http://www.w3.org/2001/XMLSchema#string

F Sánchez Gascón

http://www.w3.org/2001/XMLSchema#string

J Aspa

http://www.w3.org/2001/XMLSchema#string

J Blanquer

http://www.w3.org/2001/XMLSchema#string

J Gallardo

http://www.w3.org/2001/XMLSchema#string

J J Martín Villasclaras

http://www.w3.org/2001/XMLSchema#string

P2860

Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention

A prediction rule to identify low-risk patients with community-acquired pneumonia

Trends in infectious disease mortality in the United States during the 20th century.

Deaths: preliminary data for 2000.

Nonresolving or slowly resolving pneumonia.

Treatment and outcomes of community-acquired pneumonia at Canadian hospitals

Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatmen

Leucocyte response and anti-inflammatory cytokines in community acquired pneumonia.

Community-acquired pneumonia in chronic obstructive pulmonary disease: a Spanish multicenter study.

Hospitalized pneumonia. Outcomes, treatment patterns, and costs in urban and rural areas.

P304

960-965

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/THX.2003.017756

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

59

http://www.w3.org/2001/XMLSchema#string

P50

Rosario Menéndez

Luis Borderías

P577

2004-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8204836

http://www.w3.org/2001/XMLSchema#string

P698

15516472

http://www.w3.org/2001/XMLSchema#string

P921

P932

1746855

http://www.w3.org/2001/XMLSchema#string